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Abstract: Carbon-based nanomaterials (CBN), such as graphene nanosheets (GNS) and 
multiwalled carbon nanotubes (MWCNT), have been proposed for potential nanomedicine 
applications such as biomedical devices and carriers for drug delivery. However, our current 
understanding regarding the systemic toxicity of these CBN through intravenous (iv) injection 
is limited. In this study, we compare the immune response resulting from GNS and MWCNT 
exposure. We hypothesize that iv administration of GNS and MWCNT would result in divergent 
systemic inflammatory responses due to physicochemical differences between these two CBN. 
In the lungs of C57BL/6 mice, GNS actuate a Th2 immune response 1 day following iv admin-
istration, which consists of neutrophilic influx and a significant increase in interleukin (IL)-5, 
IL-13, IL-33, and its soluble receptor (sST2) in the bronchoalveolar lavage fluid. MWCNT 
elicited a significant increase in the messenger ribonucleic acid expression of cytokines in the 
spleen including IL-4 and IL-33, which are associated with an increase in splenic cell differ-
entiation (CD)4+ and CD8+ T-cells in C57BL/6 mice following iv injection. The observed Th2 
responses in both the lung and spleen are absent in ST2-/- mice administrated GNS or MWCNT, 
suggesting a critical role for IL-33. In conclusion, the use of GNS or MWCNT as nanocarriers 
for drug delivery may result in Th2 immune responses that are mediated through the IL-33/ST2 
axis and therefore may promote adverse allergic reactions.
Keywords: IL-33, ST2, graphene nanosheets, multiwalled carbon nanotubes, Th2 immune 
responses
Introduction
The development of diverse nanomaterials has added a new dimension to the rapidly 
expanding field of nanotechnology. The potential applications of nanomaterials range 
widely from biomedicine to mechanical engineering. One major biomedical application 
of nanomaterials is their usage in nanomedicine as diagnostic and therapeutic tools.1,2 
The advantage of utilizing nanomaterials as drug delivery systems is their capability 
of penetrating normally intact physiologic barriers and reaching a variety of molecular 
targets due to their size.3–7 Currently, our understanding and knowledge regarding the 
potential toxicity and adverse health effects resulting from exposures to nanomateri-
als is insufficient. Unintentional or intentional exposure to nanomaterials may induce 
immunotoxicity resulting in detrimental effects to immune function. In vivo studies 
have demonstrated that nanoparticles are capable of promoting inflammation or sup-
pressing immune functions.8–10 This nanoparticle-induced inflammatory response 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1733
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S44211
International Journal of Nanomedicine 2013:8
may have an impact on immune defense, and the Th1/Th2 
balance.3 Limited studies, however, have been focused on 
immune effects in vivo through iv injection, even though this 
will be a primary route for delivering nanomedicine.11
Carbon-based nanomaterials (CBN) represent a highly 
applicable subset of nanoparticles that have garnered consid-
erable interest as carriers for a variety of therapeutic agents. 
CBN consist of many different forms, including fullerenes, 
single- and multiwalled carbon nanotubes (SWCNT and 
MWCNT, respectively), and graphene nanosheets (GNS). 
MWCNT exist with a one-dimensional structure, whereas 
GNS have a two-dimensional lattice causing them to have 
markedly dissimilar geometric shapes, which may influence 
their therapeutic potential through altering their biodistri-
bution and/or toxicity. In addition to differences in shape, 
MWCNT and GNS are synthesized by different methods 
resulting in diverse physicochemical properties and catalyst 
impurities. Specifically, the MWCNT used in this study were 
∼25 nm in diameter, with a surface area of ∼113 m2/g and 
∼5 wt% Fe catalyst. Two types of GNS were also evaluated 
in this study including GNS (2) with a thickness of ∼2 nm, 
and GNS (5) with a ∼5 nm thickness. Both types of GNS, 
however, exist with a theoretical surface area of ∼2630 m2/g 
and have no metal catalyst present. This large surface area-
to-volume ratio of GNS provides an ideal platform for use 
as a drug delivery system in nanomedicine, but it may also 
disrupt immune function.
Recently, we have demonstrated that pulmonary instil-
lation of MWCNT in mice induces interleukin (IL)-33 
production and may function as an “alarmin” in response 
to nanomaterial exposure.12,13 IL-33 is a novel member of 
the IL-1 family of cytokines that includes IL-1α/β, IL-1Ra, 
and IL-18.14 Interaction of IL-33 with its receptor, ST2, pro-
motes a variety of actions from various cell types, including 
basophils, mast cells, macrophages, and Th2 cells.15,16 ST2 
is a member of the IL-1 receptor (IL-1R) family with two 
isoforms: a membrane-bound receptor (ST2) and a soluble 
receptor (sST2).17 SST2 can function as a decoy receptor 
binding IL-33 thereby inhibiting signaling through the 
membrane-bound receptor, ST2.18 In addition, the IL-33/ST2 
axis is involved in the promotion and maintenance of CD4+ 
Th2-type allergic inflammation by stimulating the production 
of IL-5 and IL-13.14 Recently, ST2 expression on cytotoxic 
(CD8+) T cells has been found under certain in vitro culture 
conditions.19
In this study, we hypothesized that intravenous 
(iv) administration of GNS and MWCNT would result 
in divergent systemic inflammatory responses due to 
physicochemical differences between these two CBN. 
Furthermore, we hypothesize that the underlying mecha-
nism responsible for these immune effects by CBN is 
through the activation of the IL-33/ST2 axis. To verify this 
hypothesis, we intravenously injected C57BL/6 and ST2 
knockout (ST2-/-) mice with MWCNT, GNS (2), or GNS (5). 
In general, C57BL/6 mice injected with CBN exhibited 
site-specific inflammatory responses with increased IL-33 
levels in the lung following GNS injection, while MWCNT 
injected mice demonstrated elevation of Th2 cytokines and 
increases in the number of CD4+ and CD8+ T-cells in the 
spleen. Furthermore, we determined the importance of the 
IL-33/ST2 axis in mediating these effects by demonstrating 
an absence of these effects in mice lacking the ST2 receptor 
when exposed to both forms of CBNs.
Materials and methods
Graphene synthesis
GNS (2) and GNS (5) were synthesized using the solvent 
exfoliation method. Briefly, for solvent exfoliation of gra-
phene, bulk graphite (∼1 g) was dispersed in 100 mL of 
N-methyl-2-pyrrolidinone and sonicated using a 1/8 inch tip 
sonicator (Branson 250; Branson Ultrasonics Corporation, 
Danbury, CT, USA) at 100 W for 2 hours. The resulting 
dispersion was filtered through a 0.45 µm nylon filter to 
obtain GNS (5). For GNS (2), the solution was subjected 
to a second sonication step for 6 hours and centrifuged at 
500 rpm for 45 minutes. The supernatant was vacuum filtered 
using a 0.45 µm nylon filter. Finally, the filtered powder 
was washed several times using deionized water to remove 
residual N-methyl-2-pyrrolidinone.
Graphene and MWCNT characterization
Commercial grade NWCNT were generously provided by 
NanoTechLabs, Inc (Yadkinville, NC, USA). The CBN used 
in this study were characterized using a Hitachi H-7600 
 electron microscope (Hitachi Ltd, Tokyo, Japan). A Dilor 
XY triple-grating spectrometer with Ar+ excitation at 
514.5 nm was used for Raman spectroscopy. The hydrody-
namic size was characterized using dynamic light scattering 
 (Nanosizer S90; Malvern Instruments, Malvern, UK). The 
zeta potential was determined using a zeta potential device 
(Zeta ZS; Malvern Instruments). For the light scattering 
measurement (dynamic light scattering and zeta potential), 
we have suspended the materials in the media consisting of 
0.6 mg/mL mouse serum albumin (MSA) and 0.01 mg/mL 
of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) in 
sterile phosphate buffered saline.
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Animals
Male C57BL/6 mice were acquired from The Jackson 
Laboratory (Bar Harbor, ME, USA) at 8–10 weeks of age. 
ST2-/- mice were generously provided by Dr Robert B Fick 
(Merck, Inc), and breeding colonies were maintained at East 
Carolina University. All animal procedures were conducted in 
accordance with the National Institutes of Health guidelines 
and approved by the East Carolina University Institutional 
Animal Care and Use Committee. All animals were treated 
humanely and with regard for alleviation of suffering.
Nanomaterials were suspended in dispersion media 
consisting of 0.6 mg/mL MSA and 0.01 mg/mL of DPPC in 
sterile phosphate buffered saline, as previously described,20 
and dispersed by cup horn sonication to ensure sterility. The 
preparation of nanomaterials dispersions in a dispersion 
medium containing MSA and DPPC ensured stability of 
the formulations. C57BL/6 and ST2-/- mice were randomly 
assigned to four treatment groups (4–8 mice/group), which 
included vehicle (dispersion media), MWCNTs, GNS (2), or 
GNS (5). Mice received a single dose of CBN by tail vein 
injection at 1 mg/kg body weight of MWCNTs, GNS (2), 
GNS (5), or dispersion media as vehicle control. For example, 
a 25 g mouse would receive 200 µL (body weight × 8) of 
0.125 mg/mL nanomaterial via injection resulting in a dose 
of 1 mg/kg. Mice were sacrificed at day 1 or 7 postinjection 
to follow the development of systemic immune responses.
BAL and cell differential counts
One or 7 days postinjection, all mice were anesthetized and 
underwent in situ bronchoalveolar lavage (BAL), as previ-
ously reported.12 Briefly, BAL was performed on the right 
lung of each mouse four separate times each with an indi-
vidual volume based on body weight (26.25 mL/kg of body 
weight) of Hanks balanced salt solution. The first aliquot 
of BAL fluid (BALF) was collected separately for cytokine 
analysis, while aliquots 2–4 were pooled. All BALF was 
centrifuged at 1000 × g for 10 minutes at 4°C. Total cells from 
lavages were pooled and counted using Cellometer® Auto 
X4 Cell Counters (Nexcelom Bioscience, LLC, Lawrence, 
MA, USA). 20,000 cells were centrifuged using Cytospin 
4 (Shandon Scientific Ltd, Cheshire, UK) and stained with 
a three-step hematology stain (Richard-Allan Scientific, 
Kalamazoo, MI, USA). Cell differential counts were deter-
mined by morphology with evaluation of 300 cells/slide.
ELISA
Samples from individual animals were run in duplicate for 
the quantification of BALF cytokine (IL-5, IL-13, IL-33, 
and sST2) levels and serum IL-5 levels using DuoSet ELISA 
kits (R&D Systems, Minneapolis, MN, USA) in accordance 
with the manufacturer’s instructions. Values are reported as 
pg/mL ± standard error of the mean.
Spleen weight and spleen cell isolation
Following BAL, spleens were removed from animals 
and weighed. Single-cell suspension of a quarter spleen 
were obtained by using the gentleMACS™ Dissociator 
(Miltenyi Biotec, Inc, Auburn, CA, USA) according to the 
 manufacturer’s recommendations. Red blood cells were 
removed using a red blood cell lysis buffer (eBioscience, 
San Diego, CA, USA). Splenocytes were resuspended in 
a final volume of 5 mL of MACs buffer (Miltenyi Biotec, 
Inc).  Quantification of total splenocytes and total live cells 
was performed by fluorescence assays for deoxyribonucleic 
acid (DNA) staining dye (Acridine orange and propidium 
iodide [Invitrogen, Eugene, OR, USA]) using Cellometer® 
Auto X4 Cell Counters  (Nexcelom Bioscience LLC). A total 
of 20,000 live splenocytes were centrifuged using Cytospin 
4 (Shandon Scientific Ltd) and stained with a three-step 
hematology stain (Richard-Allan Scientific). Spleen cell 
differential counts were determined by morphology with 
evaluation of 300 cells/slide.
Flow cytometry
Isolated cell suspensions (1 × 106 cells/sample) from spleens 
were preincubated with anti-CD16/32 (AbD Serotec, 
 Kidlington, UK) on ice for 10 minutes prior to incubation. 
Fluorescein isothiocyanate-conjugated antimouse CD4 
(L3T4) and PerCP-Cy5.5 conjugated antimouse CD8 
(Ly-2) antibodies obtained from eBioscience were used to 
stain splenocytes at room temperature for 30 minutes in the 
dark. Flow cytometric analysis of the stained splenocytes 
was performed with an Accuri C6 flow cytometer (BD 
Accuri™ Cytometers; BD Biosciences, Ann Arbor, MI, 
USA).
Histopathology
The left lung and spleen were perfused with 10% zinc 
formalin fixative and allowed to fix for 24 hours prior to 
processing. Lung and spleen tissue were processed and 
embedded in paraffin, and 5 µM sections were mounted on 
slides. Sections were stained with hematoxylin and eosin 
to detect inflammatory and morphological changes, as well 
as nanoparticle deposition. The size of CBN aggregates 
in the lung was evaluated by measuring the length at the 
longest axis (L) as well as the perpendicular axis (P). The 
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number of nanoparticle agglomerates was determined from 
representative lung sections. Spleen sections were blinded 
and  evaluated by certified pathologists from Experimental 
Pathology Laboratories (EPL, Inc, Sterling, VA, USA).
Immunofluorescence
Unstained histological spleen sections from C57BL/6 mice 
were used for immunofluorescence detection of IL-33 protein 
expression, as previously described.13 Spleen sections were 
deparaffinized and were blocked in blocking buffer (5% fil-
tered fetal bovine serum in Tris buffer saline [TBS] with 0.2% 
Tween) for 2 hours, after which the IL-33 primary antibody 
was applied at 1:100 (Novus Biologicals, LLC, Littleton, 
CO, USA) for 48 hours at 4°C. Sections were washed one 
time with TBS and two times with blocking buffer, and then 
incubated in a DyLight® 550 conjugated secondary antibody 
at 1:100 (Abcam plc, Cambridge, MA, USA) for 2 hours at 
room temperature. Following additional washes in TBS with 
0.1% Triton X, sections were coverslipped using Prolong 
gold antifade containing a 4′,6-diamidino-2-phenylindole, 
dilactate (DAPI) stain (Molecular Probes®; Molecular Probes, 
Inc, Eugene, OR, USA). Dry sections were imaged using 
DAPI and TRITC filters for nuclear- and IL-33-specific 
staining.
Quantitative Real-Time PCR
Total ribonucleic acid (RNA) from a spleen biopsy was 
isolated using a Direct-zol™ RNA MiniPrep (Zymo 
Research Corporation, Irvine, CA, USA) according to the 
manufacturer’s recommendations. Total RNA (1 µg) was 
reverse-transcribed to complementary DNA (cDNA) using 
an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Inc, Hercules, CA, USA). Quantitative real-time polymerase 
chain reaction (PCR) was performed using SsoAdvanced™ 
SYBR® Green Supermix (Bio-Rad Laboratories, Inc) and 
QuantiTect primer assays (QIAGEN, Valencia, CA, USA). 
An Applied Biosystems StepOnePlus Real-Time PCR 
System (Life Technologies, Carlsbad, CA, USA) was used 
to obtain cycle threshold (Ct) values for target and internal 
reference cDNA levels. Target cDNA levels were normalized 
to glyceraldehydes 3-phosphate dehydrogenase, an internal 
reference, using the equation 2-[∆Ct], where ∆Ct is defined as 
Ct
target
 - Ct
internal reference
. Values shown are the average of four 
independent experiments.
Statistical analyses
All data are presented as the mean ± standard error of the 
mean, and were analyzed by one-way analysis of vari-
ance (ANOVA) or two-way ANOVA, with differences 
between groups assessed using Bonferroni post hoc tests. 
Graphs and analyses were performed using GraphPad 
Prism 5 software (GraphPad Software, Inc, La Jolla, CA, 
USA). Differences were considered statistically significant 
at P , 0.05.
Results
Characterization and detection 
of GNS and MWCNT
GNS and MWCNT were characterized using transmis-
sion electron microscopy and Raman spectroscopy. As 
shown in Figure 1, GNS (2) and GNS (5) exhibited 
flake-like morphology with an area ∼4 µm2 and 25 µm2, 
while MWCNTs exhibited tubular morphology with a 
length of ∼10–20 microns and diameter of ∼20–30 nm. 
The Raman spectra exhibited strong graphitic or G-band 
(∼1590 cm-1), consistent with previous studies.12,13 
We used the G-band signal (Figure 1D, as well as Figures 
S1 and S2 in the supplementary materials) in the Raman 
spectrum to conf irm whether the black particulates 
found in the lung and spleen were GNS and MWCNT, 
concurring with previous studies.21,22 As shown in 
Table 1, the hydrodynamic sizes of MWCNT, GNS (2), 
and GNS (5) are 792.70 ± 20.30, 823.85 ± 25.60, and 
6600.00 ± 178.40 nm, respectively. The MWCNT sus-
pension displayed a zeta potential of -20.79 ± 1.52 mV, 
whereas the zeta potential of GNS (2) suspension 
was -33.17 ± 2.04 mV and the zeta potential of GNS (5) 
suspension was -28.56 ± 3.30 mV, suggesting a stable 
colloidal state of the nanomaterials.
Intravenous administration of GNS 
promotes a Th2 response in the lung 
via the IL-33/ST2 axis
We have recently reported that IL-33 drives both pulmonary 
and cardiovascular toxicity of MWCNT in C57BL/6 mice 
following pulmonary instillation; therefore, we hypoth-
esized that iv delivery of CBN may elicit similar responses 
resulting in systemic toxicity.12,13 To investigate whether 
iv injection of CBN activates the IL-33/ST2 axis, we first 
examined protein levels of IL-33 and sST2 in BALF. At 
1 day postinjection, C57BL/6 mice injected with 1 mg/kg of 
GNS (2) demonstrated a significant increase in both IL-33 
and sST2 levels in BALF compared to vehicle-injected 
mice (Figure 2A and B). IL-33 was also significantly 
increased at 1 day following a 1 mg/kg injection of GNS 
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Figure 1 Characterization of carbon-based nanomaterials. Transmission electron micrographs for (A) MWCNT, (B) GNS (2), and (C) GNS (5). (D) Raman spectrum for the 
carbon-based nanomaterials (top spectrum) exhibits a strong graphitic or G-band ∼1590 cm-1 while the animal tissue (bottom spectrum) shows no such signature. (E) Optical 
micrograph of a typical lung section exposed to GNS (5). (F) Raman G-band map of the boxed area in (E) shows that that the black spots seen in the optical micrograph are 
indeed carbon nanomaterials.
Notes: In the Raman micrograph, red and green colored areas represent a high and no intensities for G-band, respectively. Similar Raman confirmation was obtained for 
other lung and spleen sections exposed to MWCNT, GNS (2), and GNS (5) (see Supplementary materials for further details).
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets.
Table 1 Characterization of carbon-based nanomaterials in suspension
Nanomaterial Descriptive dimensions Zeta potential 
(mV)
Hydrodynamic size 
(nm)
MWCNT 25 ± 5 nm diameter, 15 ± 5 µm length -20.79 ± 1.52  792.70 ± 20.30
GNS (2) 2 ± 1 nm thick, 4 ± 1 µm2 area -33.17 ± 2.04  823.85 ± 25.60
GNS (5) 5 ± 1 nm thick, 25 ± 5 µm2 area -28.56 ± 3.30 6600.00 ± 178.4
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets.
(5) in comparison to vehicle-injected animals. In contrast 
to our previous studies that demonstrated increased IL-33 
following pulmonary instillation of MWCNT,12,13 IL-33 
did not increase within the BALF following iv injection 
of MWCNT.
Given that IL-33 induces the release of Th2 cytokines 
through the ST2 receptor in a variety of immune cells, we 
examined protein levels of IL-5, IL-13, and interferon (IFN)-γ 
in BALF of C57BL/6 and ST2-/- mice 1 or 7 days following 
a single injection of CBN. GNS (2)-injected C57BL/6 mice 
that had increased levels of IL-33 in BALF (Figure 2) also 
displayed increases in both IL-5 and IL-13 at 1 day following 
injection (Figure 3A and B). Elevation of these Th2 cytok-
ines was not observed in the BALF of ST2-/- mice at 1 day 
following CBN injection compared to vehicle (Figure 3A 
and B). A comparison between strains revealed a significant 
decrease in IL-5 and IL-13 between the C57BL/6 mice and 
the ST2-/- mice at 1 day following the injection of GNS (2). 
However, no statistically significant changes in IL-5 and 
IL-13 production in BALF of C57BL/6 and ST2-/- mice 
were found 7 days following CBN injection (Figure S3A 
and B). IFN-γ levels were not detectable in the BALF (data 
not shown).
To determine if an increase in IL-33 in BALF following 
CBN injection elicits a pulmonary inflammatory cell response, 
we examined differential cell counts from the BAL of C57BL/6 
and ST2-/- mice at 1 or 7 days  postinjection. A significant 
elevation in neutrophils was observed in C57BL/6 mice at 
1 day postinjection of 1 mg/kg GNS (2) compared to controls 
(Table 2). Eosinophils and lymphocytes were also increased 
in C57BL/6 mice 7 days postinjection of 1 mg/kg GNS (5) 
(Table 2). However, no significant differences in differential 
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Figure 2 IL-33 and sST2 production in BALF of C57BL/6 mice 1 or 7 days postinjection with MWCNT, GNS (2), or GNS (5). IL-33 and sST2 levels were determined by ELISA 
in BALF of C57BL/6 mice intravenously injected with vehicle or 1 mg/kg of MWCNT, GNS (2), or GNS (5). (A) IL-33 and (B) its soluble receptor sST2 protein levels 1 or 
7 days following injection of CBNs.
Notes: Values are expressed as the mean ± SEM (n = 4–8 per group). *P , 0.05 and ***P , 0.001 compared to vehicle controls.
Abbreviations: IL, interleukin; sST2, soluble receptor; BALF, bronchoalveolar lavage fluid; MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets; 
ELISA, enzyme-linked immunosorbent assay; CBNs, carbon-based nanomaterials; SEM, standard error of the mean; n, number.
cell counts were found in the BALF of ST2-/- mice (Table 2). 
Histological evaluation of lung sections confirmed the altered 
inflammatory cell profile in C57BL/6 mice (Figure 4). At 1 day 
postinjection, the majority of MWCNT aggregates were found 
in the pulmonary capillary lumen of C57BL/6 (Figure 4B; yel-
low arrow) and ST2-/- mice (Figure S4B; yellow arrow), while 
both types of GNS translocated from the capillary into the 
alveolar air space (Figure 4C, D, G, and H, as well as Figures 
S4C, D, G, and H). Lastly, the size of the MWCNT and GNS 
aggregates in the lung decreased in size between 1 and 7 days 
(Table S1).
Intravenous administration of MWCNT 
elicits a CD4+ Th2 response and CD8+ 
response in the spleen dependent 
on the IL-33/ST2 pathway
We evaluated Th1/Th2 inflammatory responses in the spleen 
of C57BL/6 and ST2-/- mice by measuring messenger RNA 
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Figure 3 Th2 cytokine production in BALF of C57BL/6 and ST2-/- mice 1 day postinjection with MWCNT, GNS (2), or GNS (5). Production of the Th2 cytokines, (A) IL-5 and 
(B) IL-13, were measured by ELISA in BALF from lungs of C57BL/6 and ST2-/- mice at 1 day following injection with vehicle or 1 mg/kg of MWCNT, GNS (2), or GNS (5).
Notes: Values are expressed as the mean ± SEM (n = 4–8 per group). **P , 0.01 compared to strain-matched vehicle control; ###P , 0.001 compared to C57BL/6 injected 
with GNS (2).
Abbreviations: BALF, bronchoalveolar lavage fluid; MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets; IL, interleukin; ELISA, enzyme-linked 
immunosorbent assay; SEM, standard error of the mean; n, number.
(mRNA) levels of IL-4, IL-5, IL-33 and IFN-γ. One day after 
iv injection of a single 1 mg/kg dose of MWCNT, a significant 
increase in IL-4 and IL-33 mRNA expression was observed in 
C57BL/6 mouse spleens (Figure 5A), whereas GNS injection 
did not result in any increase in cytokine mRNA expression. 
Significantly increased mRNA levels of IL-33 were observed 
in C57BL/6 mice 7 days following iv injection of 1 mg/kg 
MWCNT compared to controls  (Figure 5B). Protein levels of 
IL-33 from CBN-injected groups was notably increased in the 
spleen and not colocalized to the nucleus (Figure 6). Although 
there was a trend toward increased IL-5 levels in the spleens of 
C57BL/6 mice, the difference between CBN treated and control 
mice did not reach significance  (Figure 5A and B). A significant 
increase in the serum levels of IL-5 in C57BL/6 mice was found 
1 day after injection of 1 mg/kg GNS (5) (10.65 ± 3.88 pg/mL) 
compared to vehicle (1.95 ± 0.88 pg/mL), while no other CBN 
exposures were different from controls (data not shown). In 
contrast to C57BL/6 mice, there were no significant differences 
in cytokine mRNA expression levels at 1 or 7 days postinjection 
of CBN in ST2-/- mice, further illustrating the importance of 
the IL-33/ST2 axis (Figure 5C and D).
To further elucidate the implications of the altered cytokine 
profile in the spleen following CBN delivery, we assessed 
the proliferation of CD4+ and CD8+ T lymphocytes by flow 
cytometry at 1 and 7 days in C57BL/6 and ST2-/- mice (Fig-
ure 6). The percentage of CD4+ and CD8+ T lymphocytes in 
the spleen was significantly increased in C57BL/6 mice 1 day 
following injection with 1 mg/kg MWCNT, but not GNS, 
compared to controls (Figure 7A and B). This increase in CD4+ 
T lymphocytes remained elevated through 7 days following iv 
injection with MWCNT, whereas the percentage of CD8+ T 
lymphocytes returned to control levels by 7 days (Figure 7C 
and D). This influence of CBN on lymphocyte populations 
was dependent on ST2 expression, as it was not observed in 
ST2-/- mice (Figure 7A–D). Differential spleen cell counts 
from all treatment groups did not demonstrate significant dif-
ferences when compared to controls, except for the total cell 
count from the GNS (5) 1-day treatment (Table 3). There were, 
however, no discernible pathological differences in the spleens 
of CBN-exposed animals compared to controls. This was likely 
due to the high inflammatory cell composition of the spleen, 
thereby inhibiting our ability to detect subtle differences in 
inflammation by microscopy (data not shown).
Discussion
We have previously demonstrated that pulmonary instillation 
of MWCNT in C57BL/6 mice leads to a Th2-type immune 
response with increased numbers of inflammatory cells and 
increased Th2 cytokine levels in the lung.12,13 Furthermore, 
we have demonstrated that these MWCNT-induced Th2 
immune responses are mediated by mast cell activation in the 
pulmonary system through the IL-33/ST2 axis.13 In our cur-
rent study, we compared the systemic immune responses that 
were initiated following iv delivery of GNS and MWCNT. 
In C57BL/6 mice, iv administration of GNS and MWCNT 
resulted in the accumulation of CBN in the lung and spleen. 
In the lungs of C57BL/6 mice, the smaller sized GNS (GNS 
[2]) triggered an increase in IL-33 and sST2, resulting in a 
Th2 immune response consisting of neutrophilic influx and 
increases in IL-5 and IL-13. While delivery of MWCNT 
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in C57BL/6 mice demonstrated a Th2 immune response in 
the spleen, which consisted of increased mRNA expression 
of Th2 cytokines, including IL-4 and IL-33, as well as an 
increase in CD4+ and CD8+ T lymphocytes. By utilizing 
ST2-/- mice, we determined that the underlying mechanism 
of these CBN-induced site-specific inflammatory responses 
was mediated by the IL-33/ST2 axis.
The routes by which CBN are administered will likely dic-
tate immune responses and ultimately influence the health and 
safety of engineered nanomaterials for biomedical applica-
tions. For example, alveolar macrophages and the pulmonary 
epithelium play a crucial role in immune responses induced 
by pulmonary exposure to CBN,13,23–25 whereas iv administra-
tion of CBN may initiate an immune response through the 
activation of circulating leukocytes.26 Our previous studies 
demonstrated that MWCNT instilled through oropharyngeal 
aspiration induces IL-33 production in the lung.13 In the 
current study, however, iv injection of MWCNT leads to 
upregulation of IL-33 in the spleen instead of the lung. These 
differences in the site of IL-33 induction are likely due to dif-
ferences in accumulation sites based on routes of exposure. 
Instillation of MWCNT-induced injury to the lung epithelium 
results in the release of IL-33,13 whereas iv injection of CBN 
may allow for IL-33 to enter many organs through overcoming 
endothelial cell barriers via cellular penetration and uptake.27 
Local macrophages and the complement system are activated 
following the recognition of these CBN, leading to the recruit-
ment of systemic leukocytes and facilitating inflammation at 
sites of CBN accumulation.28,29 The use of iv delivery utilized 
in this study was selected to accurately depict the potential 
biomedical applications of these CBN. The dose used in our 
study (1 mg/kg) is within the dose range of other studies 
(0.02–5 mg/kg).30–32 However, our study demonstrates that 
even at a relatively low dose, CBN delivery still modulates the 
immune system. Therefore, at higher doses, more exaggerated 
immune responses may occur resulting in toxicity and disease. 
In addition to the 1 mg/kg CBN doses, we also examined the 
effects induced at lower doses of CBNs including 0.01 mg/
kg and 0.1 mg/kg. Neither of these lower doses administered 
intravenously was found to induce Th2 immune responses in 
the spleen or lungs (data not shown).
The translocation and biodistribution of CBN are criti-
cal factors in evaluating their potential safety in vivo. In our 
study, Raman spectroscopy confirmed the presence of 
MWCNT and GNS in both the lung and spleen following a 
single administration. Mice injected with GNS were found 
to exhibit a Th2 immune response in the lung, whereas those 
injected with MWCNT resulted in an immune response in 
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Figure 4 Histopathology in the lungs of C57BL/6 mice injected with MWCNT, GNS (2), or GNS (5). Representative histopathology of hematoxylin and eosin-stained lung 
sections from C57BL/6 mice at 1 or 7 days following (A and E) injection with vehicle, or (B and F) 1 mg/kg of MWCNT, (C and G) GNS (2), or (D and H) GNS (5).
Notes: Agglomerates of MWCNT within the pulmonary capillary are indicated by yellow arrows. Localization of GNS within the alveolar space is indicated by red arrows 
for GNS (2) and green arrows for GNS (5) at 1 or 7 days postinjection.
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets.
the spleen. These site-specific immune responses induced by 
GNS and MWCNT suggest differences in the biodistribution 
between these two CBN. A previous study has demonstrated 
that iv injection of rhenium–graphene oxide into mice leads 
to rapid clearance of this rhenium-graphene oxide from the 
bloodstream and its distribution throughout the body within 
48 hours, with the primary accumulation site being the 
lungs.33 This is consistent with our histopathological find-
ings demonstrating the accumulation of GNS in the alveolar 
spaces as early as 1 day following injection. Conversely, 
MWCNT have been shown to accumulate in the spleen fol-
lowing iv administration, irrespective of their surface char-
acteristics.34,35 These findings are consistent with our study, 
which demonstrates not only an accumulation of MWCNT 
in the spleen, but also an induction of immune responses in 
the spleen after exposure. Overall, our findings indicate dif-
ferences in organ distribution for the two types of CBN and 
thereby differences in sites of inflammation. These different 
patterns of biodistribution may be useful in developing drug 
delivery systems for specific organs. Further studies assessing 
the biodistribution of CBN are needed using fluorescence- or 
radioisotope-labeled nanomaterials to quantify nanomaterials 
in each organ.
The physicochemical properties of CBN, such as shape, 
size, surface charge, and the addition of functional groups, 
can have a dramatic impact on their biodistribution in vivo.36,37 
Compositionally, GNS and MWCNT are similar and con-
sist primarily of carbon. However, GNS and MWCNT are 
dramatically different in regard to shape, surface area, and 
the presence of metal catalysts, which may influence their 
respective biodistribution. A previous study comparing GNS 
with SWCNT has demonstrated differences in neuronal 
PC12 cell cytotoxicity possibly due to their shape and/or 
state of agglomeration.38 Similarly, in our study, differences 
in site-specific inflammatory responses are likely explained 
by the shape and agglomeration state of these CBN and their 
biological interactions with the endothelial barrier of the 
circulatory system. Our lung histology results showed that 
some agglomerated MWCNT accumulated in the pulmonary 
capillary by 1 day, but did not reach the alveolar spaces, while 
GNS clearly reached the alveolar spaces within 1 day follow-
ing injection. GNS, with their flat shape, appear to readily 
penetrate the endothelial barrier of the pulmonary capillary. 
However, MWCNT, with their tubular shape agglomerate 
easily and may not readily penetrate the endothelial barrier, 
inhibiting their entrance into the lung. An accumulating 
amount of evidence has suggested that different CBN have 
different renal clearance speed and urinary excretion rates 
due to their physicochemical properties.39 Therefore, fur-
ther studies are needed to illustrate the efficiency of renal 
clearance and urinary excretion of these CBN. The different 
sizes of GNS produced different responses in the lung, with 
smaller sized GNS being more potent at inducing a Th2 
immune response. These size-dependent differences in the 
immune response of GNS might be due to differences in 
internalization by phagocytes, since the efficient internaliza-
tion of nanomaterials by phagocytes is reported to be partly 
size dependent.40
Previous studies in our laboratory and others have dem-
onstrated that pulmonary exposure to MWCNT induces 
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Figure 5 mRNA expression of Th1/Th2 cytokines in spleens of C57BL/6 and ST2-/- mice 1 or 7 days following intravenous injection with MWCNT, GNS (2), or GNS (5). 
Real-time PCR analysis for mRNA expression of IL-4, IL-5, IL-33, and IFN-γ was performed in spleen tissue from vehicle or 1 mg/kg of MWCNT, GNS (2), or GNS (5) injected 
(A and B) C57BL/6 and (C and D) ST2-/- (C and D) mice at (A and C) 1 day and (B and D) 7 days postinjection.
Notes: All values are expressed as the mean ± SEM (n = 4 per group). *P , 0.05 compared to strain-matched vehicle control.
Abbreviations: mRNA, messenger ribonucleic acid; MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets; PCR, polymerase chain reaction; IL, interleukin; 
IFN, interferon; SEM, standard error of the mean; n, number.
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Figure 6 IL-33 protein expression in spleens of C57BL/6 mice 1 or 7 days following intravenous injection with MWCNT, GNS (2), or GNS (5). 
Note: Representative immunofluorescence images of IL-33 protein expression (red) in spleen from C57BL/6 mice at 1 or 7 days following injection with (A and E) vehicle 
or (B and F) 1 mg/kg of MWCNT, (C and G) GNS (2), or (D and H) GNS (5).
Abbreviations: IL, interleukin; MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets.
IL-33 as an alarmin to activate the immune system and may 
be a major mechanism responsible for MWCNT-induced 
cardiopulmonary toxicity.12,13,25,41 To date, however, there 
have been no studies describing the effects of CBN through 
iv injection with regards to IL-33 production. Our results 
demonstrate that injection of GNS caused a marked increase 
in IL-33 production in the lung, while MWCNT injection 
resulted in elevated IL-33 mRNA expression within the 
spleen. IL-33 has been found to be constitutively expressed 
in the epithelial cells of bronchus and small airways of 
both mice and humans with allergic asthma,42–44 as well as 
in CBN-induced  pulmonary toxicity.12,13,25 The alarmin IL-33 
released from damaged endothelial or epithelial cells may 
induce the activation of the inflammasome and promote the 
release of cytokines (such as IL-5 and IL-13) from different 
cell types including macrophages, mast cells, basophils, and 
T-helper cells.14–16 Our data supports previous IL-33 observa-
tions by showing that GNS induce transient increases in IL-33 
production in the lung,13 which consequently promotes the 
release of IL-5 and IL-13 1 day following iv administration, 
thereby leading to inflammatory cell recruitment.
The spleen is the major organ of the reticuloendothelial 
system where accumulation of MWCNT has been shown to 
occur following iv administration, irrespective of surface 
characteristics including hydrophilicity, hydrophobicity, 
and surface charge.34,35 Our results established that iv injec-
tion of MWCNT leads to the upregulation of IL-33 mRNA 
in the spleen of mice and continues to be elevated through 
7 days. While the cellular source of IL-33 remains unknown 
 following MWCNT delivery, it has been reported that stromal 
cells are a source of IL-33 mRNA and of protein expression 
in mouse spleen.45 Meanwhile, IL-4 mRNA expression was 
found to be increased in the spleen 1 day following injection 
of MWCNT. This increase in IL-4 mRNA expression might 
be due to the increase in IL-33, since a previous study has 
shown that IL-33 promotes antigen-stimulated Th2 cells to 
increase production of IL-4.46
Although ST2 has been predominantly detected on CD4+ 
Th2 cells,47 recent studies have found that ST2 is also highly 
expressed on CD8+ T cells.19,48 ST2 plays an auxiliary role 
in the differentiation of CD4+ Th2 cells, but a critical role in 
the development of an effective Th2 response.49 Signaling 
through ST2 has been found to increase transcription of a 
variety of genes in CD8+ effector T-cells, including those 
associated with differentiation, proliferation, migration, and 
adhesion.48 In addition, IL-33 has been found to be expressed 
in nonhematopoietic cells within the splenic T-cell zone, 
where the initiation and expansion of T-cell responses is 
known to occur.48 Our study shows significant increases in 
both CD4+ and CD8+ T-cells 1 day following injection of 
MWCNT, as well as the continued elevation of CD4+ T-cells 
through 7 days. In contrast, when MWCNT were injected in 
mice lacking the ST2 receptor, there was not an increase in the 
CD4+ or CD8+ T cell populations in the spleen. Maintaining 
the proper number and proportion of CD4+ and CD8+ T-cells 
is essential for optimal host defense.50 Therefore, disturbing 
this balance following CBN exposure could lead to adverse 
effects on host defense or allergic diseases. These findings 
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Figure 7 CD4 and CD8 expression on splenocytes of C57BL/6 and ST2-/- mice 1 or 7 days following intravenous injection with MWCNT, GNS (2), or GNS (5). Surface 
expression of CD4 and CD8 on splenocytes was analyzed by flow cytometry at (A and B) 1 day or (C and D) 7 days following injection with vehicle or 1 mg/kg of MWCNT, 
GNS (2), or GNS (5) in C57BL/6 and ST2-/- mice. (A and C) Each multicolor contour plot is a representative of 4–8 independent mice at 1 or 7 days postinjection. (B and D) 
Changes in CD4+ and CD8+ T lymphocytes (%) in C57BL/6 and ST2-/- mouse spleen at 1 or 7 days following intravenous injection.
Notes: Values are expressed as the mean ± SEM (n = 4–8 per group). *P , 0.05 compared to strain-matched vehicle control.
Abbreviations: CD, cell differentiation; MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets; SEM, standard error of the mean; n, number.
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Table 3 Effect of MWCNT and GNS on splenocyte population in C57BL/6 and ST2-/- mice at 1 day or 7 days following intravenous 
injection
Strain Time point Treatment Lymphocytes 
(×106 cells/mL)
Total cells 
(×106 cells/mL)
C57BL/6 1 day Vehicle 11.32 ± 1.16 13.31 ± 1.31
1 mg/kg MWCNT 12.09 ± 1.29 14.66 ± 1.48
1 mg/kg GNS (2) 12.96 ± 1.55 16.73 ± 1.74
1 mg/kg GNS (5) 16.77 ± 1.49 22.53 ± 1.49*
7 days Vehicle 10.47 ± 0.91 13.13 ± 0.93
1 mg/kg MWCNT 10.92 ± 0.53 13.91 ± 0.54
1 mg/kg GNS (2) 12.85 ± 0.24 16.68 ± 0.58
1 mg/kg GNS (5) 11.33 ± 1.41 14.71 ± 1.08
ST2-/- 1 day Vehicle 15.52 ± 0.98 17.41 ± 1.07
1 mg/kg MWCNT 13.53 ± 2.20 15.23 ± 2.34
1 mg/kg GNS (2) 13.85 ± 1.54 15.73 ± 1.39
1 mg/kg GNS (5) 16.03 ± 2.80 18.14 ± 3.36
7 days Vehicle 14.48 ± 2.20 15.68 ± 2.37
1 mg/kg MWCNT 15.13 ± 2.17 17.45 ± 2.14
1 mg/kg GNS (2) 13.47 ± 1.61 14.61 ± 1.58
1 mg/kg GNS (5) 15.25 ± 2.09 16.87 ± 2.03
Note: *P , 0.05 compared to C57BL/6 mice injected with vehicle.
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets.
clearly point to an important role for IL-33 and its receptor 
ST2 in the proliferation of CD4+ and CD8+ T-cells following 
iv administration of MWCNT. Meanwhile, these results also 
support activation of the ST2 receptor as a mechanism for 
CBN-induced systemic toxicity.
Conclusion
The unique properties of CBN – including but not limited to 
size, covalent bonding to different drugs, and high  loading 
capacity – has prompted their use in nanomedicine.51,52 
However, the safety of CBN as drug carriers remains a 
concern. In order for CBN to be used safely in drug delivery 
systems, we have to understand their interactions with the 
immune system. In the current study, we have demonstrated 
that iv injection of CBN results in site-specific immune 
responses with polarization towards a Th2 response in the 
lung and spleen. Furthermore, we validated that these CD4+ 
Th2 immune responses induced by CBN were mediated by 
the IL-33/ST2 axis. By establishing the IL-33/ST2 axis as 
a potential mechanism of CBN-induced immunotoxicity, 
IL-33 may prove to be a useful screening tool to assess 
the safety of nanomedicines. A shift in the Th1/Th2 bal-
ance by CBN could have profound effects on both host 
defense and the exacerbation of allergic diseases such as 
asthma and anaphylaxis. These different immunotoxico-
logic effects induced by iv administration of GNS and 
MWCNT are likely due to their varied physicochemi-
cal properties. Further modification of these CBN may 
be necessary to decrease the potential immunotoxicity 
related to iv delivery and to ensure their safety for use in 
nanomedicines.
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Supplementary materials
Table S1 Sizes and numbers of CBN agglomerates in the lungs
Treatment Time point L (μm) P (μm) Agglomerates 
per slide (N)
1 mg/kg  
MWCNT
1 day 63.58 ± 15.76 34.19 ± 3.46 12.79 ± 3.66
7 days 36.29 ± 2.62 25.18 ± 1.45  8.95 ± 3.13
1 mg/kg  
GNS (2)
1 day 27.10 ± 3.18 20.39 ± 2.89  8.79 ± 1.54
7 days 17.66 ± 1.41 13.88 ± 1.45  6.08 ± 0.71
1 mg/kg  
GNS (5)
1 day 20.10 ± 1.30 14.48 ± 0.92  4.98 ± 0.77
7 days  19.4 ± 1.47 14.11 ± 1.03 10.74 ± 2.07
Abbreviations: CBN, carbon-based nanomaterials; L, longest axis; P, perpendicular axis with the longest axis; N, number; MWCNT, multiwalled carbon nanotubes; GNS, 
graphene nanosheets.
A
B
Lung MWCNTs
Lung GNS (2)
2 µm
2 µm
2 µm
2 µm
Figure S2 Optical microscope images and the corresponding micro-Raman maps 
for lung sections exposed to MWCNTs and GNS. Optical microscope images and 
the corresponding micro-Raman maps for lung sections exposed to (A) MWCNTs 
and (B) GNS.
Note: In the Raman maps, the red and green colored areas indicate high and no 
intensity for G-band, respectively.
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene 
nanosheets.
A
B
C
Spleen MWCNTs
Spleen GNS (5)
Spleen GNS (2)
2 µm
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Figure S1 Optical microscope images and the corresponding micro-Raman maps 
for spleen sections exposed to MWCNTs and GNS. Optical microscope images and 
the corresponding micro-Raman maps for spleen sections exposed (A) MWCNTs, 
(B) GNS (5), and (C) GNS (2).
Note: In the Raman maps, the red and green colored areas indicate high and no 
intensity for G-band respectively.
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene 
nanosheets.
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Figure S3 Production of the Th2 cytokines, IL-5 and IL-13, were measured by ELISA in BALF from the lungs of C57BL/6 and ST2-/- mice at 7 days following injection with 
vehicle or 1 mg/kg of MWCNT, GNS (2), or GNS (5). Production of the Th2 cytokines, (A) IL-5 and (B) IL-13, were measured by ELISA in BALF from the lungs of C57BL/6 
and ST2-/- mice at 7 days following injection with vehicle or 1 mg/kg of MWCNT, GNS (2), or GNS (5).
Note: Values are expressed as the mean ± SEM (n = 4–8 per group).
Abbreviations: IL, interleukin; ELISA, enzyme-linked immunosorbent assay; BALF, bronchoalveolar lavage fluid; MWCNT, multiwalled carbon nanotubes; GNS, graphene 
nanosheets; SEM, standard error of the mean.
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Figure S4 Representative histopathology of hematoxylin and eosin-stained lung sections from ST2-/- mice at 1 or 7 days following injection with vehicle or 1 mg/kg MWCNT, 
GNS (2), or GNS (5). Representative histopathology of hematoxylin and eosin stained lung sections from ST2-/- mice at 1 or 7 days following injection with (A and E) 
vehicle or (B and F) 1 mg/kg of MWCNT, (C and G) GNS (2), or (D and H) GNS (5).
Notes: Agglomerates of MWCNT within pulmonary capillaries are indicated by yellow arrows. Localization of GNS within the alveolar space is indicated by red arrows for 
GNS (2) and green arrows for GNS (5) at 1 or 7 days postinjection.
Abbreviations: MWCNT, multiwalled carbon nanotubes; GNS, graphene nanosheets.
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